Inhibrx Biosciences, Inc.

NasdaqGS:INBX Stock Report

Market Cap: US$195.0m

Inhibrx Biosciences Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:INBX Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
20 Nov 24BuyUS$1,523,620John KayyemIndividual107,186US$14.23
03 Oct 24BuyUS$100,005Kristiina VuoriIndividual6,667US$15.00
16 Sep 24BuyUS$629,117Mark LappeIndividual40,000US$17.13
11 Sep 24BuyUS$99,992Kristiina VuoriIndividual6,636US$15.07
10 Sep 24BuyUS$671,150Mark LappeIndividual44,000US$15.29
03 Sep 24BuyUS$596,763Mark LappeIndividual40,000US$16.31
29 Aug 24BuyUS$99,960Kristiina VuoriIndividual7,140US$14.00
28 Aug 24BuyUS$139,800Kimberly ManhardIndividual10,000US$13.98
23 Aug 24BuyUS$1,037,328Douglas ForsythIndividual75,000US$14.07
21 Aug 24BuyUS$518,282Mark LappeIndividual40,000US$12.97
05 Jun 24BuyUS$997,024John KayyemIndividual57,549US$17.89
04 Jun 24BuyUS$4,927,580John KayyemIndividual286,786US$18.24

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of INBX?
Owner TypeNumber of SharesOwnership Percentage
General Public770,6505.32%
VC/PE Firms1,064,0267.35%
Public Companies1,157,9268%
Hedge Funds1,787,70512.3%
Individual Insiders2,753,35419%
Institutions6,942,24348%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 87.36% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
12.4%
Viking Global Investors LP
1,787,705US$24.1m0%0.07%
8%
Sanofi
1,157,926US$15.6m0%no data
7.35%
Perceptive Advisors LLC
1,064,026US$14.3m0%0.52%
7.32%
John Kayyem
1,059,046US$14.3m0%no data
6.39%
Mark Lappe
925,413US$12.5m0%no data
6.02%
HighTower Advisors, LLC
871,754US$11.7m11.5%0.02%
5.75%
BlackRock, Inc.
832,732US$11.2m0.11%no data
4.82%
Sofinnova Investment, Inc.
697,916US$9.4m32.4%0.7%
4.06%
The Vanguard Group, Inc.
588,323US$7.9m-3.19%no data
3.55%
Brendan Eckelman
513,888US$6.9m0%no data
3.03%
PFM Health Sciences, LP
439,283US$5.9m224%0.48%
2.48%
Woodline Partners LP
358,436US$4.8m0%0.03%
1.98%
Slotnik Capital, LLC
286,962US$3.9m-26%2.04%
1.8%
Geode Capital Management, LLC
260,029US$3.5m1.92%no data
1.76%
Millennium Management LLC
255,336US$3.4m-1.18%no data
1.55%
Douglas Forsyth
224,564US$3.0m0%no data
1.38%
Caption Management, LLC
199,508US$2.7m-0.2%0.11%
1.33%
Acadian Asset Management LLC
192,498US$2.6m34.2%0.01%
1.19%
State Street Global Advisors, Inc.
172,904US$2.3m-1.97%no data
1.14%
Kennedy Capital Management LLC
164,976US$2.2m-0.43%0.05%
1%
Schonfeld Strategic Advisors LLC
144,178US$1.9m0%0.01%
0.97%
CM-CIC Asset Management SA
140,149US$1.9m0%0.01%
0.96%
ArrowMark Colorado Holdings, LLC
139,682US$1.9m-13.2%0.03%
0.8%
Northern Trust Global Investments
116,513US$1.6m0.35%no data
0.37%
Susquehanna International Group, LLP, Asset Management Arm
52,873US$712.2k-27%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/06/02 11:26
End of Day Share Price 2025/06/02 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Inhibrx Biosciences, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Reni BenjaminCitizens JMP Securities, LLC
Michael YeeJefferies LLC